UiPath reported quarterly earnings of nine cents per share, which beat the analyst consensus estimate of three cents. Quarterly revenue of $424 million missed the analyst consensus estimate of $425.36 ...

Intel shares jumped 10.6% to $22.88 in the pre-market trading session. Here are some other stocks moving in pre-market ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in ...

JPMorgan raised the firm’s price target on AnaptysBio (ANAB) to $42 from $36 and keeps an Overweight rating on the shares. The firm updated ...

Guggenheim raised the firm’s price target on AnaptysBio (ANAB) to $52 from $36 and keeps a Buy rating on the shares following the company’s Q4 ...

AnaptysBio (NASDAQ:ANAB – Get Free Report) will likely be releasing its earnings data before the market opens on Monday, March 10th. Analysts expect AnaptysBio to post earnings of ($1.55) per share ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and tr ...

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $1.59 per share a year ago. These figures are ...